BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Mechie NC, Röver C, Cameron S, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol 2014; 6(10): 759-765 [PMID: 25349647 DOI: 10.4254/wjh.v6.i10.759]
URL: https://www.wjgnet.com/1948-5182/full/v6/i10/759.htm
Number Citing Articles
Yanhua Li, Jiuping Wang, Juan Wang, Yunfeng Xiao, Bin Xu, Hongwei Li, Liu Yang, Xiaoke Hao, Yueyun Ma. SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest ChinaVirology Journal 2017; 14(1) doi: 10.1186/s12985-017-0708-6
Samar E. Ghanem, Maha Elsabaawy, Nashwa shebl, Eman Abdelsameea, Warda Othman, Fathia I. EL‑Bassal, Gamalat A. Elgedawy, Dalia M. Elsabaawy, Marwa L. Helal. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapyExpert Review of Anti-infective Therapy 2020; 18(9): 947 doi: 10.1080/14787210.2020.1771180
Elena L. Enache, Anca Sin, Liviu S. Enache, Ligia Bancu. Triplex High-Resolution Melting Assay for the Simultaneous Assessment of IFNL3 rs12979860, ABCB11 rs2287622, and RNF7 rs16851720 Genotypes in Chronic Hepatitis C PatientsThe Journal of Molecular Diagnostics 2017; 19(6): 857 doi: 10.1016/j.jmoldx.2017.07.005